Cargando…
411 Mrd. €, 11,9 %
Autor principal: | Kuhn, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130979/ https://www.ncbi.nlm.nih.gov/pubmed/35612606 http://dx.doi.org/10.1007/s00103-022-03539-6 |
Ejemplares similares
-
Secondary mutations in t(4;11) leukemia patients
por: Prelle, C, et al.
Publicado: (2013) -
(4R,11R)-9-(1-hydroxypropan-2-yl)-4,11-diphenyl-1,3,5,7,9-pentaazatricyclo[5.3.1.0(4,11)]undecane-2,6-dithione
por: Wang, Meng, et al.
Publicado: (2011) -
MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017) -
MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023) -
The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism
por: Kühn, Alessa, et al.
Publicado: (2016)